SCHEMBL16334152

SCHEMBL16334152

O=C(O)N1CC=C(c2ccccc2)O1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.35
MAPK1 P28482 1/20 0.35
TSHR P16473 3/20 0.35
CHRM2 P08172 7/20 0.35
CHRM4 P08173 7/20 0.35
CHRM5 P08912 7/20 0.35
CHRM1 P11229 7/20 0.35
CHRM3 P20309 7/20 0.35
ALDH1A1 P00352 4/20 0.34
MAPT P10636 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 2/20 0.33
GAA P10253 2/20 0.33
HPGD P15428 1/20 0.33
ABCC4 O15439 1/20 0.33
PTGS1 P23219 1/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31474039 0.59 CFTR (0.36) SMN1; SMN2MAPK1CHRM2CHRM4CHRM5
SCHEMBL8710435 0.59 LMNA (0.40) SMN1; SMN2TSHRALDH1A1MAPTLMNA
SCHEMBL23123903 0.59 POLB (0.37) CHRM2CHRM4CHRM5CHRM1CHRM3
Biphenyl SCHEMBL750993 0.59 ALDH1A1 (0.69) SMN1; SMN2TSHRALDH1A1MAPTL3MBTL1
Biphenyl SCHEMBL377457 0.59 ALDH1A1 (0.69) SMN1; SMN2TSHRALDH1A1MAPTL3MBTL1
Biphenyl SCHEMBL190337 0.59 ALDH1A1 (0.69) SMN1; SMN2TSHRALDH1A1MAPTL3MBTL1
Biphenyl SCHEMBL1396421 0.59 ALDH1A1 (0.69) SMN1; SMN2TSHRALDH1A1MAPTL3MBTL1
Biphenyl SCHEMBL1839538 0.59 ALDH1A1 (0.69) SMN1; SMN2TSHRALDH1A1MAPTL3MBTL1
SCHEMBL11506718 0.57 SMN1; SMN2 (0.45) SMN1; SMN2MAPK1TSHRALDH1A1MAPT
SCHEMBL25260022 0.57 HSD17B3 (0.42) SMN1; SMN2ALDH1A1MAPTHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160151335-A1 METHODS OF MODULATING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2016-06-02 US disclosed
EP-3013341-A1 METHODS OF MODULATING CFTR ACTIVITY Proteostasis Therapeutics, Inc. (US) 2016-05-04 EP disclosed
WO-2014210159-A1 METHODS OF MODULATING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160151335-A1 METHODS OF MODULATING CFTR ACTIVITY CFTR, HSP90B1, SERPINB1 SMN1; SMN2 1740/4885MAPK1 3176/4885TSHR 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.